{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:10:50Z","timestamp":1783901450055,"version":"3.55.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2020-0026_s_006_w2aab3b7c40b1b6b1aab1c16b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements\n                      <jats:bold>\n                        <jats:sub>.<\/jats:sub>\n                      <\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0026_s_007_w2aab3b7c40b1b6b1aab1c16b2Aa\">\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0026_s_008_w2aab3b7c40b1b6b1aab1c16b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA\/IIIB were diagnosed in 55%\/45% of patients, respectively. N2\/N3 nodes were diagnosed in 60%\/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0026_s_009_w2aab3b7c40b1b6b1aab1c16b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The real-world study demonstrated a broad heterogeneity in the management o f stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2020-0026","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T04:52:53Z","timestamp":1590641573000},"page":"209-220","source":"Crossref","is-referenced-by-count":13,"title":["Care of patients with non-small-cell lung cancer stage III \u2013 the Central European real-world experience"],"prefix":"10.2478","volume":"54","author":[{"given":"Milada","family":"Zemanova","sequence":"first","affiliation":[{"name":"1st Faculty of Medicine of Charles University in Prague , Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pirker","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubos","family":"Petruzelka","sequence":"additional","affiliation":[{"name":"1st Faculty of Medicine of Charles University in Prague , Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Zboz\u00ednkova","sequence":"additional","affiliation":[{"name":"Institute of Biostatistic and Analyses, Faculty of Medicine, Masaryk University , Brno , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Jovanovic","sequence":"additional","affiliation":[{"name":"Clinic for Pulmonology, Clinical Centre of Serbia , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Rajer","sequence":"additional","affiliation":[{"name":"Institute of Oncology , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Bogos","sequence":"additional","affiliation":[{"name":"National Koranyi Institute of TB and Pulmonology , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunta","family":"Purkalne","sequence":"additional","affiliation":[{"name":"Pauls Stradins Clinical University Hospital , Riga , Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Ceriman","sequence":"additional","affiliation":[{"name":"Clinic for Pulmonology, Clinical Centre of Serbia , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Comprehensive Oncology Center, Nov\u00fd Ji\u010d\u00edn , Liberec Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Richter","sequence":"additional","affiliation":[{"name":"Comprehensive Oncology Center , Liberec , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jir\u00ed","family":"Kufa","sequence":"additional","affiliation":[{"name":"Clinic for Pneumology & Tuberculosis, Faculty of Medicine, Palack\u00fd University , Olomouc , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Jakubikova","sequence":"additional","affiliation":[{"name":"Clinic for Pneumology & Tuberculosis, Faculty of Medicine, Masaryk University , Brno , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Zemaitis","sequence":"additional","affiliation":[{"name":"Hospital of LUHS Kauno Klinikos , Kauno , Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marketa","family":"Cernovska","sequence":"additional","affiliation":[{"name":"Thomayer Hospital , Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Koubkova","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, University Hospital Motol , Prague , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Vilasova","sequence":"additional","affiliation":[{"name":"Comprehensive Oncology Center and Multiscan , Pardubice , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dieckmann","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Farkas","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Spasic","sequence":"additional","affiliation":[{"name":"Institute for Oncology and Radiology of Serbia , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[{"name":"Institute of Biostatistic and Analyses, Faculty of Medicine, Masaryk University , Brno , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Tiefenbacher","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virag","family":"Hollosi","sequence":"additional","affiliation":[{"name":"National Koranyi Institute of TB and Pulmonology , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juraj","family":"Kultan","sequence":"additional","affiliation":[{"name":"Clinic for Pneumology & Tuberculosis, Faculty of Medicine, Palack\u00fd University , Olomouc , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iveta","family":"Kolarov\u00e1","sequence":"additional","affiliation":[{"name":"Comprehensive Oncology Center and Multiscan , Pardubice , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Votruba","sequence":"additional","affiliation":[{"name":"1st Faculty of Medicine of Charles University in Prague , Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"2026071213222444107_j_raon-2020-0026_ref_001_w2aab3b7c40b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Nappi A, Gallicchio R, Simeon V, Nardelli A, Pelagalli A, Zupa A, et al. [F-18] FDG-PET\/CT parameters as predictors of outcome in inoperable NSCLC patients. Radiol Oncol 2015; 49: 320-6. doi: 10.1515\/raon-2015-0043","DOI":"10.1515\/raon-2015-0043"},{"key":"2026071213222444107_j_raon-2020-0026_ref_002_w2aab3b7c40b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Eberhardt WE, De Ruysscher D, Weder W, Le P\u00e9choux C, De Leyn P, Hoffmann H, et al. Panel members. 2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 2015; 26: 1573-88. doi: 10.1093\/annonc\/mdv187","DOI":"10.1093\/annonc\/mdv187"},{"key":"2026071213222444107_j_raon-2020-0026_ref_003_w2aab3b7c40b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14. doi: 10.1097\/JTO.0b013e31812f3c1a","DOI":"10.1097\/JTO.0b013e31812f3c1a"},{"key":"2026071213222444107_j_raon-2020-0026_ref_004_w2aab3b7c40b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39-51. doi: 10.1016\/j.jtho.2015.09.009.","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"2026071213222444107_j_raon-2020-0026_ref_005_w2aab3b7c40b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 2008; 26: 3552-9. doi: 10.1200\/ JCO.2007.13.9030","DOI":"10.1200\/JCO.2007.13.9030"},{"key":"2026071213222444107_j_raon-2020-0026_ref_006_w2aab3b7c40b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014; 383: 1561-71. doi: 10.1016\/S0140-6736(13)62159-5","DOI":"10.1016\/S0140-6736(13)62159-5"},{"key":"2026071213222444107_j_raon-2020-0026_ref_007_w2aab3b7c40b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Betticher DC, Hsu Schmitz SF, Totsch M, Hansen E, Joss C, von Briel C, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006; 94: 1099-106.","DOI":"10.1038\/sj.bjc.6603075"},{"key":"2026071213222444107_j_raon-2020-0026_ref_008_w2aab3b7c40b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Sher DJ, Fidler MJ, Liptay MJ, Koshy M. Comparative effectiveness of neo-adjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer 2015; 88: 267-74. doi: 10.1016\/j.lungcan.2015.03.015","DOI":"10.1016\/j.lungcan.2015.03.015"},{"key":"2026071213222444107_j_raon-2020-0026_ref_009_w2aab3b7c40b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Thomas M, Rube C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008; 9: 636-48. doi: 10.1016\/S1470-2045(08)70156-6","DOI":"10.1016\/S1470-2045(08)70156-6"},{"key":"2026071213222444107_j_raon-2020-0026_ref_010_w2aab3b7c40b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Garrido P, Gonzalez-Larriba JL, Insa A, Provencio M, Torres A, Isla D, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007; 25: 4736-42.","DOI":"10.1200\/JCO.2007.12.0014"},{"key":"2026071213222444107_j_raon-2020-0026_ref_011_w2aab3b7c40b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Barl\u00e9si F, Doddoli C, Torre JP, Giudicelli R, Fuentes P, Thomas P, et al. Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy. Eur J Cardiothorac Surg 2005; 28: 629-34. doi: 10.1016\/j.ejcts.2005.06.018","DOI":"10.1016\/j.ejcts.2005.06.018"},{"key":"2026071213222444107_j_raon-2020-0026_ref_012_w2aab3b7c40b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010 28: 2181-90. doi: 10.1200\/JCO.2009.26.2543","DOI":"10.1200\/JCO.2009.26.2543"},{"key":"2026071213222444107_j_raon-2020-0026_ref_013_w2aab3b7c40b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Ma L, Men Y, Feng L, Kang J, Sun X, Yuan M, et al. A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer. Radiol Oncol 2019; 53: 6-14. doi: 10.2478\/raon-2019-0006","DOI":"10.2478\/raon-2019-0006"},{"key":"2026071213222444107_j_raon-2020-0026_ref_014_w2aab3b7c40b1b6b1ab2b1c14Aa","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919-29. doi: 10.1056\/ NEJMoa1709937"},{"key":"2026071213222444107_j_raon-2020-0026_ref_015_w2aab3b7c40b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Zhang Z, Sun J. Interval censoring. Stat Methods Med Res 2010; 19: 53-70. doi: 10.1177\/0962280209105023","DOI":"10.1177\/0962280209105023"},{"key":"2026071213222444107_j_raon-2020-0026_ref_016_w2aab3b7c40b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2016; 34: 953-62. doi: 10.1200\/JCO.2015.64.8824","DOI":"10.1200\/JCO.2015.64.8824"},{"key":"2026071213222444107_j_raon-2020-0026_ref_017_w2aab3b7c40b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, et al. INSIGHT study team. Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: The INSIGHT Study. 10: 1370-4. J Thorac Oncol 2015; 10: 1370-4. doi: 10.1097\/ JTO.0000000000000621","DOI":"10.1097\/JTO.0000000000000621"},{"key":"2026071213222444107_j_raon-2020-0026_ref_018_w2aab3b7c40b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016; 387: 1415-26. doi: 10.1016\/S0140-6736(16)00004-0","DOI":"10.1016\/S0140-6736(16)00004-0"},{"key":"2026071213222444107_j_raon-2020-0026_ref_019_w2aab3b7c40b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Hofman P. ALK in Non-Small Cell Lung Cancer (NSCLC): pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers 2017; 9: pii: E107. doi: 10.3390\/cancers9080107","DOI":"10.3390\/cancers9080107"},{"key":"2026071213222444107_j_raon-2020-0026_ref_020_w2aab3b7c40b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, et al. Real-world outcomes in patients with unresected stage III non-small cell lung cancer. Med Oncol 2019; 36: 24. doi: 10.1007\/s12032-019-1249-1","DOI":"10.1007\/s12032-019-1249-1"},{"key":"2026071213222444107_j_raon-2020-0026_ref_021_w2aab3b7c40b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, et al. Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer. Future Oncol 2019; 15: 2943-53. doi: 10.2217\/ fon-2018-0939","DOI":"10.2217\/fon-2018-0939"},{"key":"2026071213222444107_j_raon-2020-0026_ref_022_w2aab3b7c40b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Moore S, Leung B, Wu J, Ho C. Real-world treatment of stage III NSCLC: the role of trimodality treatment in the era of immunotherapy. J Thorac Oncol 2019; 14: 1430-9. doi: 10.1016\/j.jtho.2019.04.005","DOI":"10.1016\/j.jtho.2019.04.005"},{"key":"2026071213222444107_j_raon-2020-0026_ref_023_w2aab3b7c40b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Fernandes AT, Mitra N, Xanthopoulos E, Evans T, Stevenson J, Langer C, et al. The impact of extent and location of mediastinal lymph node involvement on survival in stage III non-small cell lung cancer patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 340-7. doi: 10.1016\/j.ijrobp.2011.05.070","DOI":"10.1016\/j.ijrobp.2011.05.070"},{"key":"2026071213222444107_j_raon-2020-0026_ref_024_w2aab3b7c40b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Van der Meer FS, Schramel FM, Van Vulpen M, El Sharouni SY. Feasibility of concomitant chemoradiotherapy in daily practice for patients with NSCLC stage III. Anticancer Res 2016; 36: 4673-6. doi: 10.21873\/anticanres.11019","DOI":"10.21873\/anticanres.11019"},{"key":"2026071213222444107_j_raon-2020-0026_ref_025_w2aab3b7c40b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-86. doi: 10.1016\/S0140-6736(09)60737-6","DOI":"10.1016\/S0140-6736(09)60737-6"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/raon\/54\/2\/article-p209.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2020-0026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:56:28Z","timestamp":1783900588000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2020-0026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,5,28]]},"published-print":{"date-parts":[[2020,5,28]]}},"alternative-id":["10.2478\/raon-2020-0026"],"URL":"https:\/\/doi.org\/10.2478\/raon-2020-0026","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]}}}